An oligopoly distributor transforming into a specialty-services platform—Cencora’s margin mix improves even as drug-price and customer concentration risks pressure revenue optics.
Overview
Cencora (formerly AmerisourceBergen, rebranded in 2023) is a mission-critical intermediary in global pharma distribution and one of the U.S. “Big Three” distributors alongside McKesson and Cardinal, collectively managing 90%+ of U.S. drug volume. Cencora’s core segment, U.S. Healthcare Solutions (~89% of revenue), distributes branded, generic, and specialty drugs to ~65,000 providers, with revenue concentrated in large, long-duration contracts—most notably Walgreens Boots Alliance (~24% of revenue; contract through 2029). International Healthcare Solutions, expanded by Alliance Healthcare, provides distribution across 50+ countries and adds geographic diversification. Strategically, Cencora is moving beyond low-margin logistics into higher-margin specialty services: MSOs (OneOncology; retina platform), GPOs, manufacturer services (PharmaLex), and World Courier’s advanced cold-chain logistics for biologics and cell/gene therapies. The investment case hinges on an oligopoly moat plus improving margin mix, balanced against customer concentration, regulatory pricing risk (IRA/340B), leverage, and acquisition integration execution.